Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: J Immunol. 2016 Sep 26;197(9):3639–3649. doi: 10.4049/jimmunol.1600402

Figure 4. Minimal HIF-2α association with Marco, in contrast to NRF2, which is required for enhanced efferocytosis.

Figure 4

(A) Schematic of Marco gene regulator regions, including Enhancer (E), Promoter (P), and ARE element. (B) Chromatin precipitation for HIF-2α on 3 P (PRM1-3) and 3 E (ENC1-3) regions each. (C) Chromatin precipitation for NRF2 on Marco. (D) Nuclear translocation of NRF2 in control vs Hif-2αfl/fl LysMcre Mϕs and induction of indicated NRF2 target genes. (E) Nrf2 siRNA tests (vs scrambled/scr) reduces MARCO in Hif-2αfl/fl LysMcre Mϕs. Efferocytosis efficiency in control Hif-2αfl/fl vs. Hif-2αfl/fl LysMcre Mϕs treated with indicated siRNA (Scr vs Nrf2). * indicates < 0.05 relative to control. (F) NRF2 agonist induces MARCO and enhances efferocytosis. WT bone marrow derived macrophages were treated with 20uM Sulforaphane, NRF2 agonist, for 24hrs, prior to blotting (nNRF2 = nuclear NRF2) and efferocytosis.